Omega-3 Fatty Acids and Cardiovascular Disease: Are There Benefits?

Current Treatment Options in Cardiovascular Medicine

Volumn 18, Issue 11, 2016, Pages

  Bowen, Kate J ^a   Harris, William S ^b   Kris Etherton, Penny M ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTH DAKOTA   (United States)

Author keywords

Cardiovascular disease; DHA; EPA; Fish; Fish oil supplements; Omega 3 fatty acids

Indexed keywords

DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIET SUPPLEMENTATION; FISH; FOOD INTAKE; HEART PROTECTION; HUMAN; PRIMARY PREVENTION; REVIEW; SECONDARY PREVENTION;

EID: 84991454545     PISSN: 10928464     EISSN: 15343189     Source Type: Journal    
DOI: 10.1007/s11936-016-0487-1     Document Type: Review

References (49)

1. Bang HO, Dyerberg J, Nielsen AB. Plasma lipid and lipoprotein pattern in Greenlandic West-coast Eskimos. Lancet. 1971;1(7710):1143–5.
2. Dyerberg J, Bang HO. Haemostatic function and platelet polyunsaturated fatty acids in Eskimos. Lancet. 1979;2(8140):433–5.
3. Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet. 1989;2(8666):757–61.
4. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet. 1999;354(9177):447–55.
5. Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione. Circulation. 2002;105(16):1897–903.
6. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369(9567):1090–8. doi:10.1016/s0140-6736(07)60527-3.
7. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1223–30.
8. Whelton SP, He J, Whelton PK, et al. Meta-analysis of observational studies on fish intake and coronary heart disease. Am J Cardiol. 2004;93(9):1119–23. doi:10.1016/j.amjcard.2004.01.038.
9. He K, Song Y, Daviglus ML, et al. Accumulated evidence on fish consumption and coronary heart disease mortality: a meta-analysis of cohort studies. Circulation. 2004;109(22):2705–11. doi:10.1161/01.cir.0000132503.19410.6b.
10. Zheng J, Huang T, Yu Y, et al. Fish consumption and CHD mortality: an updated meta-analysis of seventeen cohort studies. Public Health Nutr. 2012;15(4):725–37. doi:10.1017/s1368980011002254.
11. U.S. Food and Drug Administration. Omega-3 fatty acids and coronary heart disease. Docket No. 2003Q-0401. 2004. http://www.fda.gov/Food/IngredientsPackagingLabeling/LabelingNutrition/ucm073992.htm#omega3. Accessed 9 June 2016.
12. Chowdhury R, Warnakula S, Kunutsor S, et al. Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. Ann Intern Med. 2014;160(6):398–406. doi:10.7326/m13-1788.
13. del Gobbo LC. Omega-3 polyunsaturated fatty acid biomarkers and coronary heart disease: pooling project of 19 cohort studies. JAMA Intern Med. 2016;176(8):1155–66. doi:10.1001/jamainternmed.2016.2925. Meta-analysis of 19 observational studies; biomarker concentrations of seafood-derived omega-3 PUFAs were associated with a lower risk of fatal CHD.
14. Wang DD, Li Y, Chiuve SE, et al. Association of specific dietary fats with total and cause-specific mortality. JAMA Intern Med. 2016;176(8):1134–45. doi:10.1001/jamainternmed.2016.2417. Analysis of two large prospective cohorts; intake of marine-derived omega-3 PUFAs was associated with lower total mortality (comparing extreme quintiles of intake).
15. Kromhout D, Giltay EJ, Geleijnse JM. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med. 2010;363(21):2015–26. doi:10.1056/NEJMoa1003603.
16. Rauch B, Schiele R, Schneider S, et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation. 2010;122(21):2152–9. doi:10.1161/circulationaha.110.948562.
17. Galan P, Kesse-Guyot E, Czernichow S, et al. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ. 2010;341:c6273. doi:10.1136/bmj.c6273.
18. Bosch J, Gerstein HC, Dagenais GR, et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367(4):309–18. doi:10.1056/NEJMoa1203859.
19. The Risk and Prevention Study Collaborative Group. n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med. 2013;368(19):1800–8. doi:10.1056/NEJMoa1205409. Treatment with daily n-3 fatty acids (850–882 mg EPA and DHA), in addition to the standard of care, did not reduce cardiovascular disease or death in patients at high CVD risk without previous MI.
20. Rice HB, Bernasconi A, Maki KC, et al. Conducting omega-3 clinical trials with cardiovascular outcomes: proceedings of a workshop held at ISSFAL 2014. Prostaglandins Leukot Essent Fatty Acids. 2016;107:30–42. doi:10.1016/j.plefa.2016.01.003. Limitations of recent omega-3 PUFA investigations and experimental design issues to consider in future trials.
21. Balk EM, Adam GP, Langberg V, et al. Omega-3 fatty acids and cardiovascular disease: an updated systematic review. Evidence Report/Technology Assessment No. 223. (Prepared by the Brown Evidence-based Practice Center under Contract No. 290-2015-00002-I.) AHRQ Publication No. 16-E002-EF. In: Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services, editors. Rockville, MD; 2016. Systematic review of 61 RCTs and 37 observational studies of omega-3 PUFAs and CVD risk factors or outcomes.
22. Murray RK, Bender DA, Botham KM, et al. Harpers illustrated biochemistry. 29th ed. New York: McGraw-Hill; 2012.
23. Plourde M, Cunnane SC. Extremely limited synthesis of long chain polyunsaturates in adults: implications for their dietary essentiality and use as supplements. Appl Physiol Nutr Metab. 2007;32(4):619–34. doi:10.1139/H07-034.
24. Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol. 2011;58(20):2047–67. doi:10.1016/j.jacc.2011.06.063.
25. U.S. Department of Agriculture, Agricultural Research Service. USDA National Nutrient Database for Standard Reference 28 Software v.2.6.1. 2016. https://ndb.nal.usda.gov. Accessed 22 June 2016.
26. U. S. Food and Drug Administration. Mercury levels in commercial fish and shellfish (1990–2010). 2014. http://www.fda.gov/Food/FoodborneIllnessContaminants/Metals/ucm115644.htm. Accessed 28 June 2016.
27. Dietary Guidelines Advisory Committee. Scientific report of the 2015 dietary guidelines advisory committee. In: U.S. Department of Agriculture, U.S. Department of Health and Human Services, editors. 2015. Review of the scientific evidence from a national advisory committee to inform the Dietary Guidelines for Americans.
28. Gil A, Gil F. Fish, a Mediterranean source of n-3 PUFA: benefits do not justify limiting consumption. Br J Nutr. 2015;113 Suppl 2:S58–67. doi:10.1017/s0007114514003742. Describes the macro- and micronutrient composition of fish and seafood products.
29. Dietary Guidelines for Americans 2015. In: U.S. Department of Agriculture, U.S. Department of Health and Human Services, editors. 8th ed. Washington, DC: U.S. Government Printing Office; 2015. Food-based recommendations for the health of Americans aged 2 +; includes 8 oz. per week of a variety of seafood for the general population.
30. Whelan J, Rust C. Innovative dietary sources of n-3 fatty acids. Annu Rev Nutr. 2006;26:75–103. doi:10.1146/annurev.nutr.25.050304.092605.
31. Vannice G, Rasmussen H. Position of the academy of nutrition and dietetics: dietary fatty acids for healthy adults. J Acad Nutr Diet. 2014;114(1):136–53. doi:10.1016/j.jand.2013.11.001. Position of the Academy of Nutrition and Dietetics on dietary fat for the healthy adult population; includes two or more servings of fatty fish per week.
32. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106(21):2747-57.
33. Lichtenstein AH, Appel LJ, Brands M, et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation. 2006;114(1):82–96. doi:10.1161/circulationaha.106.176158.
34. Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women—2011 update: a guideline from the American Heart Association. J Am Coll Cardiol. 2011;57(12):1404–23. doi:10.1016/j.jacc.2011.02.005.
35. Jacobson TA, Maki KC, Orringer CE, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 2. J Clin Lipidol. 2015;9(6 Suppl):S1–122 e1. doi:10.1016/j.jacl.2015.09.002. The National Lipid Association’s recommendations for patient-centered management of dyslipidemia; includes ≥ 2 servings (1 serving = 3.5–4 oz.) of fish/seafood (preferably oily) per week for the prevention of atherosclerotic CVD.
36. Lewis CJ. Letter regarding dietary supplement health claim for omega-3 fatty acids and coronary heart disease (Docket No. 91N-0103). In: U. S. Food and Drug Administration, Center for Food Safety and Applied Nutrition, editors. 2000
37. Burr ML, Sweetnam PM, Fehily AM. Letters to the editor: diet and reinfarction. Eur Heart J. 1994;15:1152–4.
38. Burr ML, Ashfield-Watt PA, Dunstan FD, et al. Lack of benefit of dietary advice to men with angina: results of a controlled trial. Eur J Clin Nutr. 2003;57(2):193–200. doi:10.1038/sj.ejcn.1601539.
39. Kris-Etherton PM, Harris WS. Adverse effect of fish oils in patients with angina? Curr Atheroscler Rep. 2004;6(6):413–4.
40. Rischio and Prevenzione Investigators. Efficacy of n-3 polyunsaturated fatty acids and feasibility of optimizing preventive strategies in patients at high cardiovascular risk: rationale, design and baseline characteristics of the Rischio and Prevenzione study, a large randomised trial in general practice. Trials. 2010;11:68. doi:10.1186/1745-6215-11-68.
41. Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368(14):1279–90. doi:10.1056/NEJMoa1200303.
42. ASCEND Investigators. ASCEND: a study of cardiovascular events in diabetes. http://rum.ctsu.ox.ac.uk/ascend/. Accessed 14 June 2016.
43. ASCEND: a study of cardiovascular events in diabetes. 2015. https://clinicaltrials.gov/ct2/show/NCT00135226. Accessed 28 June 2016.
44. Manson JE, Bassuk SS, Lee IM, et al. The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials. 2012;33(1):159–71. doi:10.1016/j.cct.2011.09.009.
45. Vitamin D and Omega-3 Trial (VITAL). 2016. https://clinicaltrials.gov/ct2/show/NCT01169259. Accessed 28 June 2016.
46. Pradhan AD, Manson JE. Update on the vitamin D and Omega-3 trial (VITAL). J Steroid Biochem. 2016;155(Pt B):252–6. doi:10.1016/j.jsbmb.2015.04.006.
47. Amarin Corporation plc. Research and Development: The REDUCE-IT. 2016. http://www.amarincorp.com/products.html. Accessed 28 June 2016.
48. A study of AMR101 to evaluate its ability to reduce cardiovascular events in high risk patients with hypertriglyceridemia and on statin. The primary objective is to evaluate the effect of 4 g/day AMR101 for preventing the occurrence of a first major cardiovascular event. (REDUCE-IT). 2016. https://clinicaltrials.gov/ct2/show/NCT01492361. Accessed 28 June 2016.
49. Outcomes study to assess statin residual risk reduction with Epanova in high CV risk patients with hypertriglyceridemia (STRENGTH). 2016. https://clinicaltrials.gov/ct2/show/NCT02104817. Accessed 28 June 2016.